Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Colonic Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Rectal Neoplasms 1Polycystic Ovary Syndrome 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphangioleiomyomatosis 1Liver Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Chemoprevention 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 61Bevacizumab 42Oxaliplatin 24Doxorubicin 22Radiosurgery 20Gemcitabine 20Fluorouracil 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17Capecitabine 17lenvatinib 16Cisplatin 16atezolizumab 13Leucovorin 13Radiotherapy 11tremelimumab 10Cyclophosphamide 10Carboplatin 10Irinotecan 9Ipilimumab 9Drug Therapy 9Everolimus 8Cryosurgery 8toripalimab 7fludarabine 7Sunitinib 7Chemotherapy, Adjuvant 7Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Neoplasms × Resveratrol × Clear all
NCT02261844 2017-03-30

Resveratrol and Human Hepatocyte Function in Cancer

University of Louisville

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡